Remove 2025 Remove Clinical Pharmacology Remove RNA
article thumbnail

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development

Alta Sciences

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.

article thumbnail

Beyond ELISA: the future of biomarker validation

Drug Target Review

For example, the European Medicines Agency (EMA), in its Regulatory Science Strategy to 2025 , has highlighted the critical role of biomarker discovery, qualification and utilisation in accelerating precision medicine. Clinical Pharmacology & Therapeutics. Available from: [link] Bakker E, Hendrikse NM, Ehmann F, et al.